AXSM

Over the past six months (approximately April 2026 - October 2026), Axsome Therapeutics' stock (AXSM) increased by 47.64% from October 6, 2025, to October 5, 2026, but has recently declined by approximately 15% over the past three months and by -15.6% in the last month. Key events include the Q2 2026 Earnings Report on August 10, 2026, which showed growing revenue but continued unprofitability. The COO sold 10,000 shares on September 3, 2026, and the CEO sold 49,664 shares on August 7, 2026, both through pre-set trading plans. Positive news in September 2026, such as a Mizuho analyst noting a 32% rise in new prescriptions for Auvelity and the company highlighting accelerating prescription growth following sales-force expansion and the launch of Auvelity for Alzheimer's disease agitation, led to a 6% jump in AXSM stock. In April 2026, the company secured FDA approval for an expanded use of Auvelity to treat agitation associated with dementia due to Alzheimer's disease in adults. Axsome Therapeutics is scheduled to report its Q3 2026 financial results on November 2, 2026.